Development of a verified osteoarthritis risk scale based on a cross-sectional study of clinical and anamnestic parameters and pharmacological anamnesis of patients

Autor: I. Yu. Torshin, А. М. Lila, N. V. Zagorodniy, А. G. Nazarenko, О. N. Tkacheva, Е. N. Dudinskaya, L. I. Alekseeva, Е. А. Taskina, I. V. Sarvilina, О. А. Shavlovskaya, A. B. Danilov, Т. B. Minasov, А. N. Galustyan, S. I. Malyavskaya, А. N. Gromov, Е. Yu. Egorova, L. V. Vasilyeva, E. F. Evstratova, I. V. Gogoleva, L. E. Fedotova, М. I. Udovika, V. A. Maximov, А. S. Povzun, О. А. Gromova
Jazyk: ruština
Rok vydání: 2023
Předmět:
Zdroj: Фармакоэкономика, Vol 16, Iss 1 (2023)
Druh dokumentu: article
ISSN: 2070-4909
2070-4933
DOI: 10.17749/2070-4909/farmakoekonomika.2023.158
Popis: Objective: the development and verification of a scale for identifying patients at high risk of osteoarthritis (OA).Material and methods. The results of the analysis of a sample of patients aged 35–90 years from the database of the Institute of Trace Elements (n=3440), which included information on clinical and anamnestic, diagnostic parameters and pharmacotherapy of patients, including patients with OA (n=107), are presented. To analyze information about patients, modern methods of data analysis proposed within the topological theory of pattern recognition were used.Results. Based on the analysis of the sample, a 100-point scale of 27 points was developed which allows to identify patients at high risk of OA (sensitivity 88%, specificity 100%). For patients with high scores on the scale, a kind of “preemptive” prescription of symptomatic slowacting drugs for osteoarthritis (SySADOA) based on highly purified substances of chondroitin sulfate (CS) and glucosamine sulfate (GS) is promising. The evidence for CS/GS is extensive and has been reviewed previously.Conclusion. Early adoption of preventive measures (including the usage of SySADOA – CS/GS) in patients with a high score on the developed scale may reduce the risk of OA.
Databáze: Directory of Open Access Journals